Article info

Download PDFPDF

Thrombocytosis and STAT5 activation in chronic myelogenous leukaemia are not associated with JAK2 V617F or calreticulin mutations

Authors

  • Samir K Turakhia Department of Laboratory Medicine, Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio, USA PubMed articlesGoogle scholar articles
  • Gurunathan Murugesan Department of Laboratory Medicine, Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio, USA PubMed articlesGoogle scholar articles
  • Claudiu V Cotta Department of Laboratory Medicine, Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio, USA PubMed articlesGoogle scholar articles
  • Karl S Theil Department of Laboratory Medicine, Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Claudiu V Cotta, Cleveland Clinic, 9500 Euclid Avenue/L-30, Cleveland, OH 44195 USA; cottac{at}ccf.org
View Full Text

Citation

Turakhia SK, Murugesan G, Cotta CV, et al
Thrombocytosis and STAT5 activation in chronic myelogenous leukaemia are not associated with JAK2 V617F or calreticulin mutations

Publication history

  • Received November 8, 2015
  • Revised December 13, 2015
  • Accepted December 14, 2015
  • First published January 11, 2016.
Online issue publication 
July 20, 2016

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.